drugset / Trial / NCT02271282

Estradiol-Receptor Blockade in Older Men and Women

NCT02271282

Phase 1 Completed 40 enrolled Mayo Clinic
RandomizedCrossoverTriple-blindBasic science

Summary

Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer

Timeline

Start
2014-12
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Toremifene Small molecule Oral
Background Ghrelin Peptide 0.3 ug/kg Intravenous
Background Growth Hormone Releasing Hormone Unknown 0.3 ug/kg Intravenous

Indications

No indication recorded.